Olopatadine selectively blocks histamine H1 receptor and stabilizes mast cells. Thus, it prevents histamine binding to its receptors and inhibits mast cell degranulation & histamine release. It also decreases chemotaxis and inhibits the activation of eosinophil.
Olpadin Eye Drops: Each ml contains Olopatadine Hydrochloride USP equivalent to Olopatadine 1 mg.
Olpadin DS Eye Drops: Each ml contains Olopatadine Hydrochloride USP equivalent to Olopatadine 2 mg.
Olpadin 7 Eye Drops: Each ml contains Olopatadine Hydrochloride USP equivalent to Olopatadine 7 mg.
Preservative: Sodium Perborate BP 0.01%.
Vehicle: Olpadin and Olpadin DS Eye Drops: Polyvinyl Alcohol USP 1.4%, Olpadin 7 Eye Drops: Povidone K-17
Olpadin, Olpadin DS & Olpadin 7 are indicated for the treatment of ocular itching associated with allergic conjunctivitis.
Olpadin: Instill 1 drop in the affected eye(s) twice daily.
Olpadin DS: Instill 1 drop in the affected eye(s) once daily.
Olpadin 7 : Instill 1 drop in the affected eye(s) once daily.
Contraindicated in patients who are hypersensitive to Olopatadine Hydrochloride or any other component of the preparation.
Blurred vision, temporary burning & stinging, dry eye, foreign body sensation, hyperemia, dysgeusia
Olopatadine has low drug interaction potential as systemic levels of Olopatadine achieved a?er ocular dosing are negligible.
Use in Pregnancy There are no adequate and well-controlled studies in pregnant women. Olopatadine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Use in Lactation It is not known whether Olopatadine passes into breast milk. However, caution should be exercised when Olopatadine is administered to a nursing mother.
Use in Pediatric: Safety and effectiveness in children for Olopatadine 0.1% is below the age of 3 years and Olopatadine 0.2% & 0.7% is below 2 years have not been established.
Use in Geriatric No overall differences in safety and effectiveness have been observed between elderly and younger patients.
FR
DE
